Consegna is a specialty pharmaceutical company reformulating known, safe drugs and creates long-acting injectable (LAI) medications with improved clinical and economic benefits. These long-acting drug formulations enable a single administration to provide a therapeutic effect ranging from several days to many weeks or months. The firm's product pipeline focuses on therapeutic areas with high non-adherence, or where LAIs can solve specific drug delivery challenges. Employing Consegna Pharma's Computational Drug Delivery⢠technology, principals of the frm are able to design LAIs more quickly than the legacy practice and with reduced regulatory and technical risk. Management also take advantage of the accelerated 505(b)(2) FDA regulatory pathway by focusing on off-patent medications
